The effectiveness of treatments for Kashin–Beck disease: a systematic review and network meta-analysis
This study aims to evaluate the efficacy of treatments for Kashin–Beck disease (KBD).
We searched PubMed, Cochrane Central Register of Controlled Trials, Embase, Web of Science, SinoMed, Chinese National Knowledge Infrastructure, reference lists and published systematic reviews and registries of ongoing trials through May 2015 for randomised controlled trials (RCTs) of treatments for KBD. Outcomes of interest were pain, function, stiffness, overall clinical improvement, radiographic improvement (X-ray) and adverse events. Frequentist network meta-analyses were conducted using random-effects consistency model to assess the efficacy of treatments for KBD.
Forty-four RCTs with 9815 participants were included in the review. In children or adolescents, selenium (risk ratio 1.88, 95% confidence interval (CI) 1.51–2.33), vitamin C (2.03, 1.40–2.95) and aspirin (2.14, 1.12–4.08) were effective for radiographic structure improvement. In adults, chondroitin plus glucosamine was the best for pain (standardised mean difference 1.46, 95% CI 1.07–1.85), followed by intra-articular injection of hyaluronic acid (IAH) (1.09, 0.70–1.48), chondroitin (0.84, 0.47–1.21), diclofenac (0.63, 1.18–1.08), naproxen (0.55, 0.12–0.98), meloxicam (0.52, 0.03–1.01) and glucosamine (0.40, 0.13–0.67) compared to placebo, with similar results for other clinical outcomes in adults. However, the strength of most evidence was limited by the small number of trials with low to moderate quality.
• There were 23 nutraceuticals, pharmaceuticals and surgical and complementary treatments assessed for Kashin–Beck disease (KBD) in randomised trials.
• Among the 23 treatments, chondroitin, glucosamine, IAH and non-steroid anti-inflammatory drugs are more effective than placebo to relieve symptoms for adults with KBD.
• Selenium supplement is more effective than placebo for radiographic improvement in children or adolescents.
• The efficacy of surgeries, aspirin, vitamin C and complementary treatments for KBD has not been established yet.
KeywordsBeck disease Efficacy Kashin Network meta-analysis Randomised controlled trials Systematic review Treatments
KZ conceptualised and designed the study. KZ and JLH screened the literature and selected the study. KZ extracted data and accessed the quality of trials, conducted the analysis and wrote the draft of the manuscript. QZ wrote part of the discussion. WZ and BD advised on the analysis and the representation of the results. All authors contributed to the intellectual interpretation of the findings and approved the final manuscript.
QZ was supported by the Innovation Research Grant from the University of Electronic Science and Technology, Chengdu, China.
Compliance with ethical standards
- 2.Moreno-Reyes R, Suetens C, Mathieu F, Begaux F, Zhu D, Rivera MT, Boelaert M, Neve J, Perlmutter N, Vanderpas J (1998) Kashin-Beck osteoarthropathy in rural Tibet in relation to selenium and iodine status. N Engl J Med 339(16):1112–1120. https://doi.org/10.1056/NEJM199810153391604 CrossRefPubMedGoogle Scholar
- 8.Li L, Wang Q, Tian JH, Yang KH, Tian HL, Shi CH, Jiang J, Wu TX, Liao YJ (2013) The relationship between the exposure and metabolism of iodine and Kaschin-Beck disease:a systematic review. Chinese Journal of Evidence-Based Pediatrics: 176–180 [In Chinese]. https://www.cjebp.net/CN/abstract/abstract9054.html
- 12.Wang FQ, Wang ZW, Ping ZG, Guo X (2005) Epidemiological investigation of the declined prevalence of Kashin-Beck disease in Linyou County, Shaanxi Province, China. Chin J Endemiol 06:637–638 [in Chinese]Google Scholar
- 13.Li FZ, Deng JY, Yang RM, Li DW, Ma GJ, Liao P, Hou CH, Zheng YT, Zhang L, Wu G (2006) Investigating report on prevalence rate of Kaschin-Beck disease in adults in Sichuan Province in 2005. Endemic Dis Bull 01:23–25 [in Chinese]Google Scholar
- 19.General office of endemic disease control, People’s Republic of China (1983) X-ray criteria of treatment effect on Kashin-beck disease (trial)Google Scholar
- 20.Ministry of Health, People’s Republic of China (1996) The judging of treatment effect on Kashin-beck disease (WS/T 79-1996)Google Scholar
- 21.Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schunemann HJ (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383–394. https://doi.org/10.1016/j.jclinepi.2010.04.026 CrossRefPubMedGoogle Scholar
- 22.Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, Kessels AG, Guyatt GH, Group GW (2014) A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 349:g5630. https://doi.org/10.1136/bmj.g5630 CrossRefPubMedGoogle Scholar
- 27.Higgins JPT, Green S (editors) (2011) Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from http://www.cochrane-handbook.org/.
- 28.da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Juni P, Trelle S (2016) Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 387(10033):2093–2105. https://doi.org/10.1016/S0140-6736(16)30002-2 CrossRefPubMedGoogle Scholar
- 29.Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 18(4):476–499. https://doi.org/10.1016/j.joca.2010.01.013 CrossRefGoogle Scholar
- 34.Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg MC, Wells G (2005) Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev (2):CD002946. https://doi.org/10.1002/14651858.CD002946.pub2
- 35.Zou K, Wong J, Abdullah N, Chen X, Smith T, Doherty M, Zhang W (2016) Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 75(11):1964–1970. https://doi.org/10.1136/annrheumdis-2015-208387 CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Trigkilidas D, Anand A (2013) The effectiveness of hyaluronic acid intra-articular injections in managing osteoarthritic knee pain. Ann R Coll Surg Engl 95(8):545–551. https://doi.org/10.1308/003588413X1362996004943210.1308/rcsann.2013.95.8.545
- 37.Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G (2006) Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev (2):CD005321. https://doi.org/10.1002/14651858.CD005321.pub2
- 40.Quan W, Xiu-xia L, Lun L, Jin-hui T, Ke-hu Y, Tai-xiang W, Yong-jian L (2013) Correlation between selenium and Kaschin-Beck disease. Chin J Evid Based Med 13(12):1421–1430Google Scholar
- 48.Chen ZL, Ma JM (1979) “Aspirin for Kashin-Beck disease: A preliminary observation on the efficacy.” Medical Journal of Chinese People’s Liberation Army(02):128. [in Chinese] Google Scholar
- 49.Niu GH, Zhang BZ, Hou SF (1990) The effect of half dose of selenium supplementation on prevention and treatment of Kaschin Beck disease Chinese Journal of Endemic Diseases 9(2):99–100 [in Chinese] Google Scholar